Article | October 22, 2021

An Expedited Development And Manufacturing Process To Support A COVID-19 Vaccine

By Kevin Thompson, Technical Director, Process Engineering Project Management Group, at Pall

iStock-1213713667-viral-vector-virus

Over the years, I’ve worked on countless projects with many customers – each one unique. But during the COVID-19 pandemic, we had the opportunity to work with the University of Oxford and AstraZeneca by supporting the rapid development and scale up of their COVID-19 vaccine, ChAdOx1-S /AZD1222 (now sold under the brand names Vaxzevira and COVISHIELD) – and that felt truly different. We joined a consortium led by the University of Oxford’s Jenner Institute to develop, scale up, and manufacture the vaccine. The process development and manufacturing work took place while clinical trials were still ongoing – typically, a huge risk, but one that was worth taking given the significant public health threat posed by SARS-CoV-2.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: